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Homocysteine is a sulfur-containing amino acid formed from methionine metabolism. Hyperhomocyst(e) inemia is an independent risk factor for the development of atherosclerosis 1, 2 . In 1969, McCully described extensive arterial thrombosis and atherosclerosis in 2 children, establishing the linkage between homocysteine and vascular disease 3 . Since then, many reports have reaffirmed this linkage 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12 . But it was only in 1994 that cardiovascular disease was correlated with hyperhomocyst(e) inemia in renal transplant patients 13 . Efforts to identify factors known to influence homocysteine metabolism succeeded; however, although homocysteine concentrations can be successfully modulated with treatment 14, 15 , we do not yet know the influence of such modulation on cardiovascular disease.
Immunosuppression after renal transplantation potentially could enhance hyperhomocyst(e)inemia -and its future modulation prevent it. We tested the former hypothesis -that immunosuppression after renal transplantation would enhance hyperhomo-cyst(e)inemia -in a cross-sectional study on three groups of patients divided according to presence or absence of cyclosporine in the treatment regimen. We have also assessed the factors known to influence homocysteine metabolism in this population.
SUBJECTS AND METHODS
Fasting blood samples were collected for analysis of total homocysteine (tHcy) by high-performance liquid chromatography with fluorescence detection. Normal serum total homocysteine concentration values ranged from 5.5 to 17 mmol/l.
Plasma folate and vitamin B12 levels were measured by radioimmunoassay. Serum creatinine, total cholesterol, LDL cholesterol (low-density lipoprotein), HDL cholesterol (high-density lipoprotein), and triglycerides were determined using standard automated clinical chemistry laboratory techniques. Creatinine clearance was estimated from the Cochkcroft-Gault formula 16 . Whole blood cyclosporine through levels were analyzed with TDx Immunosuppressant Drug AssaysCyclosporine Monoclonal Whole Blood (Abbot Laboratories).
Twenty-nine renal transplant patients were studied at least 12 months after transplantation, undergoing treatment with fixed doses of immunosuppressive drugs for 6 months and having serum creatinine levels of less than 2.0 mg/dl. Study patients were not under treatment with any vitamin supplement following the transplantation. End-stage renal disease was due to chronic glomerulonephritis (n=11), chronic pyelonephritis (n=5), nephrosclerosis (n=5), diabetic nephropathy (n=3), polycystic kidney disease (n=2) or undetermined cause (n=3).
Patients were divided into 2 groups according to immunosuppression therapy:
Group I: 20 renal transplant patients on cyclosporine, azathioprine, and prednisone;
Group II: 9 renal transplant patients on azathioprine and prednisone;
And the third group enrolled comprised renal donors (control group):
Group III: 7 renal graft donors for groups I and II.
Results were expressed as mean ± standard deviation (SD). Continuous variables were compared by t-test, and the chi-square test was applied for estimating the occurrence of categorical variables. Pearson Product Moment correlation was used for unadjusted correlation between continuous variables. Multiple regression analysis was performed to identify independent predictors of tHcy. Statistical significance was defined as tests with a probability of < 0.05. The statistical analyses were performed in SigmaStat 2.0 software.
RESULTS
Characteristics of patients and control groups are summarized in Table 1 .
The mean plasma homocyst(e) inemia concentration was 18.07 ± 8.29 mmol/l in renal transplant recipients: 16.55 ± 5.6 mmol/l (group I, with cyclosporine), and 21.44 ± 12.1 mmol/ l (group II, without cyclosporine) (NS).In renal donors, tHcy was significantly lower (9.07 ± 3.06 mmol/l; group I + group II vs. group III, p<0.008).
Pearson correlation was tested using age, body weight, dialysis duration before transplantation, transplant duration, serum creatinine, estimated creatinine clearance, cholesterol, HDLcholesterol and LDL -cholesterol, trig- Total serum homocysteine in the cyclosporine-treated group had no one independent regressor in this study, when age, body weight, dialysis duration before transplantation, transplant duration, serum creatinine, cyclosporine trough level, estimated creatinine clearance, cholesterol, HDL-cholesterol and LDL-cholesterol, triglycerides, folate level, vitamin B12 level, azathioprine dose, prednisone dose, and cyclosporine dose were included.
We found no cases of hyperhomocyst(e)inemia in the control group. In contrast, 38% of renal recipients had hyperhomocyst(e)inemia: 7 cases (35%) in the cyclosporine-treated group and 4 (45%) in the group not receiving cyclosporine, based on plasmatic normal levels. If there was a positive and direct relationship between serum and plasma homocysteine levels, we would state, based on the Kang et al. classification 12 , that for patients receiving cyclosporine, 35% had moderate hyperhomocyst(e)inemia; for patients not receiving cyclosporine (group II), 33% had moderate and 12% had intermediate hyperhomocyst(e) inemia.
DISCUSSION
Homocysteine is a sulfur-containing non-essential amino acid that is formed as a product of methionine metabolism. Its chemical structure is 2-amin-4-mercaptobutanoic acid.
Methionine is converted to homocysteine through S-adenosyl methionine. Then homocyst(e)ine undergoes either remethylation or transsulfuration. In the remethylation pathway, homocysteine is salvaged by the acquisition of a methyl group in a reaction catalyzed by methionine synthase. Vitamin B12 (cobalamin) is the precursor of methylcobalamin, which is the cofactor for methionine synthase, and N5-methyl-tetrahydrofolate is the methyl donor in this reaction. Remethylation can also be catalyzed by betaine-homocysteine methyl transferase 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 . Under conditions in which an excess of methionine is present or cysteine synthesis is required, homocysteine condenses with serine to form cystathionine in a reaction catalyzed by the vitamin-B6-dependent enzyme, cystathionine β-synthase 17, 18, 19, 20, 22, 24, 25 . Cystathionine is subsequently hydrolyzed to form α-ketobutyrate and cysteine, which may in turn be incorporated into glutathione or further metabolized to sulfate and excreted in the urine 18, 26 . Clinical studies involving homocysteine generally rely on the measurement of total plasma homocysteine, which includes homocysteine, mixed disulfides involving homocysteine, homocysteine thiolactone, free homocysteine, and protein-bound homocysteine 17, 27 . The sum of all free and protein-bound forms is referred as total homocysteine (tHcy) or as homocyst(e)ine to emphasize the uncertain distribution of reduced sulfhydryl and oxidized disulfide moieties 28 . This correct but cumbersome convention is frequently overlooked but needs to be acknowledged 17 . Normal total plasma homocysteine concentration ranges from 5 to 15 mmol per liter in the fasting state 22 , and serum levels are known to be higher 29, 30 12 . An oral challenge (100 mg/kg) can be given to persons suspected of hyperhomocyst(e)inemia who have normal fasting homocyst(e)ine levels. Plasma homocyst(e)ine concentrations are determined before methionine challenge and 4 and 8 hours afterwards. Hyperhomocyst(e)inemia is considered to be present if the concentration of tHcy is more than 2 standard deviations above the mean 11 . The oral methionine challenge is more useful for subjects with cystathionine-β-synthase deficiency than for those with methylenetetrahydrofolate reductase deficiency 4, 20 .
There are genetic and acquired causes of homocyst(e)inemia. Rare inborn errors of metabolism result in elevation of plasma and urine homocysteine. The homozygous deficiency of cystathionine β-synthase is the most common cause and is associated with plasma tHcy levels up to 400 mmol per liter 20 . Atherothrombotic complications frequently develop in young adulthood and are often fatal 9 . Heterozygotes typically have plasma levels in the range of 20 to 40 mmol per liter 1, 4 . A homozygous deficiency of N5-N10-methylene-tetrahydrolfolate reductase (MTHFR) carries a much worse prognosis, in part due to the complete lack of effective therapy 20 . Kang et al. reported a more common genetic defect that is phenotypically expressed as a thermolabile form of MTHFR that has a prevalence of 5% in the general population and 17% among patients with coronary disease 31, 32 . Deficiencies in vitamin cofactors required for homocysteine metabolism, like folate, vitamin B12, and B6, may promote hyperhomocyst(e)inemia, and supplementation can normalize concentrations of homocysteine 14, 15, 21, 33, 34 . Negative correlations have been related between folate, cobalamin, and tHcy 1, 6, 35, 36, 37, 38, 39, 40, 41 . Several drugs can interfere with the metabolism of homocysteine such as methotrexate, phenytoin, and theophylline 20 . In spite of in vitro studies reporting renal metabolism of homocysteine, and in vivo studies in which the concentration of homocysteine in the plasma of rats was increased due to its substantial uptake and metabolism by the kidney 42, 43, 44 , van Guldener et al. showed no net renal extraction of homocysteine in fasting humans 45, 46 . These findings rekindle a search for "uremia-induced" extrarenal defects in homocysteine metabolism 18 . Although it was said that urinary homocysteine excretion was minimal 42 , hyperfiltrating diabetic subjects with supernormal glomerular filtration rates may have subnormal fasting tHcy levels 47 . Indeed, it should be stressed that glomerular filtration rate and cystatin C are independent determinants of tHcy, and they are much better determinants than is creatinine concentration 48, 49 . Although there is a direct relationship between tHcy and KT/V (an index of dialysis adequacy), the dialytic amount of tHcy did not seem to contribute significantly to its removal 38 . In 1969, McCully described prominent arterial damage in patients with a deficiency in methionine metabolism and homocysteinemia and hypothesized that homocysteine derivatives played a role in the pathogenesis of atherosclerosis 3 . Histopathologic hallmarks of homocysteine-induced vascular injury include intimal thickening, elastic lamina disruption, smooth muscle hypertrophy, marked platelet accumulation, and the formation of platelet-enriched occlusive thrombi 3, 5 . The postulated effects involve oxidative damage to vascular endothelial cells and increased proliferation of vascular smooth cells after oxidative metabolism of homocysteine to homocystine and homocysteine thiolactone. Oxidative modification of low-density lipoprotein (LDL) promotes the formation of foam cells, which in turn yields another source of reactive species 50 . A direct endothelial cell injury can also occur 51 . It seems that prostacyclin production is unlikely to result from homocysteine effects 52, 53, 54 . Prolonged exposure of endothelial cells to homocysteine impairs production of nitric oxide 55 and alters the normal antithrombotic phenotype of the endothelium by attenuation of endothelial cell tissue-plasminogen-activator binding sites 56, 57 , activation of factor V 58 , inhibition of protein 59, 60 and heparan sulfate 6 and decreasing endothelial antithrombotic activity due to changes in thrombomodulin function 60 . There is abundant epidemiological evidence of the association between hyperhomocyst(e)inemia and atherothrombosis either in normal or endstage renal failure population 1, 2, 46, 7, 8, 9, 10, 11, 12 .
Patient death from cardiovascular causes is an important reason for transplant failure over time 62 . Fifty to sixty percent of deaths are directly attributable to cardiovascular disease. Future advances in long-term renal graft survival will depend largely on the success of preventing myocardial infarction and death in this patient population 63 . Renal transplant recipients are prone to atherosclerotic complications, and risk factors independently associated in a multivariate analysis after accounting for pretransplant vascular disease were: increasing patient age, diabetes mellitus, male gender, cigarette smoking, hypertension, and elevated serum cholesterol levels. The data had also suggested that an increased prevalence of known risk factors explains the high incidence of cardiovascular disease in the renal transplant recipient 64 . Immunosuppressive drugs that prevent allograft rejection could exacerbate atherosclerosis. However, this possibility could not explain all cases, so efforts were made to identify other risk factors.
Fasting hyperhomocyst(e)inemia is an independent risk factor for coronary artery disease, stroke, peripheral vascular atherosclerosis, and for arterial and venous thromboembolism. The interaction of hyperhomocyst(e)inemia with hypertension and smoking is strong, and the combined effect is more than multiplicative. The combined effect of homocysteine and cholesterol is additive 10 . Massy et al. were pioneers in the study of homocysteine metabolism in renal transplant patients, and they found by stepwise discriminant analysis and by logistic regression analysis in 42 patients that homocysteine was also a risk factor associated with cardiovascular disease in this population 13 . Total homocysteine is significantly increased in renal transplant patients 35, 36, 37, 40, 41, 65 as compared to healthy controls 35, 65 or a matched renal dysfunction group 35, 40, 65 . Determinants of homocyst(e)ine concentration in renal transplant patients are listed in table 2.
In 1996, Arnadottir et al. reported that renal transplant recipients on cyclosporine had significantly higher plasma homocyst(e)inemia than those not on cyclosporine (19.7 ± 7.6 vs. 16.2 ± 4.8 mmol/l, mean ± S.D) 35 . But in 1998, they described no correlation between plasma homocyst(e)ine and cyclosporine concentration or doses of cyclosporine, prednisone, and azathioprine 40 . It is not known how cyclosporine could interfere in homocysteine metabolism, but cyclosporine could be a methyl donor, since during its hepatic metabolism, hydroxylation and Ndemethylation are important reactions 66 . Moreover, Ducloux et al reported that patients with or without cyclosporine had similar plasma homocyst(e)ine concentrations 36, 37 . Woodside et al found no difference in homocysteinemia between patients receiving cyclosporin (n = 39, homocysteine 11.0 ± 1.5 mmol/l), and patients receiving prednisolone + azathioprine (n = 16, 10.8 ± 1.6 mmol/l, mean ± S.D.), although there was a significant correlation between homocysteine and serum cyclosporin concentration in the sub-group of patients receiving that immunosuppressive regimen (r = 0.42, P < 0.05) 67 . Gilfix et al showed a negative correlation of tHcy to cyclosporine when using C2 levels (level of cyclosporine measured in the second hour after administration), but which was consistent with the negative correlation between creatinine concentration and C2 68 . In our previous study, although tHcy was similar under the two schemes of immunosuppressors, there was a strong negative correlation between tHcy and the cyclosporine trough level (r= -0.79 and p= 0.01) 65 . As yet, we have not found a difference between tHcy levels with or without cyclosporine or an effect of cyclosporine trough level on homocyst (e)inemia.
Azathioprine, another immunosuppressive drug, causes absolute or relative deficiency in folate and/or cobalamin, a condition also reported to increase homocyst(e)inemia.
Födinger et al observed no effect of azathioprine on homocysteine metabolism 39 . In contrast, Mazouz et al concluded that the addition of azathioprine to the standard immunosuppressive regimen further increased Hcy serum levels in renal transplant recipients, which could be mediated by absolute or relative deficiency in folate 69 . In adult male rats, mean plasma homocysteine concentration after treatment with cortisol was substantially lower, compared with the level of plasma homocysteine in the control group, indicating a significant protective effect of steroid on plasma homocysteine levels 70 .
We did not observe a correlation between azathioprine or prednisone doses and homocyst(e)inemia in either of the recipient groups or between cyclosporine doses in the group taking cyclosporine.
It had been previously reported that there was no difference in homocysteine levels between individuals treated with tacrolimus and cyclosporine, and there was no correlation between homocysteine and immunosuppressant trough levels or the development of histologically diagnosed chronic graft nephropathy 71 . Although vitamin B6 treatment resulted in a 22.1% reduction in geometric-mean post-methionine-loading increases in plasma total homocysteine levels, and folic acid plus vitamin B12 treatment caused a 26.2% reduction in geometric-mean fasting plasma total homocysteine levels 15 , their effect on cardiovascular disease is not known.
We must stress that hyperhomocyst(e)inemia is an important problem in the follow-up of renal transplant recipients. Renal recipients with renal function loss and the older recipients are the most at risk population. Since hyperhomocyst(e)inemia increases cardiovascular disease risk and patient survival, efforts have to be made to search for other possible determinants of homocyst(e)inemia and to reduce it. 
